Prelude Therapeutics (PRLD) Cash from Investing Activities (2019 - 2026)

Prelude Therapeutics (PRLD) has 8 years of Cash from Investing Activities data on file, last reported at $8.5 million in Q1 2026.

• For the quarter ending Q1 2026, Cash from Investing Activities fell 86.33% year-over-year to $8.5 million; the trailing twelve-month figure through Mar 2026 stood at -$228000.0 (down 100.19% YoY), and the FY2025 full-year result was $53.5 million, down 40.73% from the prior year.
• Cash from Investing Activities grew to $8.5 million in Q1 2026, from -$60.3 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $62.2 million in Q1 2025 to a low of -$75.4 million in Q2 2023.
• A 5-year average of $11.7 million and a median of $15.0 million in 2023 frame the typical range for Cash from Investing Activities.
• Across the five-year window, Cash from Investing Activities soared 15474.28% in 2022 and slumped 372.8% in 2025, its largest moves.
• Tracing PRLD's Cash from Investing Activities over 5 years: stood at $1.4 million in 2022, then soared by 470.92% to $7.7 million in 2023, then jumped by 185.91% to $22.1 million in 2024, then tumbled by 372.8% to -$60.3 million in 2025, then surged by 114.09% to $8.5 million in 2026.
• Business Quant data shows PRLD's Cash from Investing Activities at $8.5 million in Q1 2026, -$60.3 million in Q4 2025, and $40.1 million in Q3 2025.